What Factors Are Escalating the Demand Across the Adeno-Associated Virus Vector-Based Gene Therapy Market?

0
0

The increasing prevalence of genetic disorders and the growing adoption of gene therapy have propelled substantial expansion in the AAV vector-based gene therapy domain. According to detailed industry evaluation, the Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market was valued at USD 5.718 billion in 2024 and is projected to reach USD 70.67 billion by 2035, exhibiting a CAGR of 25.68% during the forecast period. AAV1, AAV2, AAV5, AAV6, AAV8, and AAV9 serotypes remain among the most sought-after vector platforms globally due to their low immunogenicity, broad tissue tropism, and ability to deliver therapeutic genes for long-term expression. Furthermore, the rising prevalence of genetic disorders, growing focus on personalized medicine, and supportive government initiatives are broadening the adoption base across hematological malignancies, neurological disorders, cardiovascular diseases, ophthalmic diseases, and oncology.

The market is driven by advancements in gene editing technologies and increasing prevalence of genetic disorders. Key players including Spark Therapeutics, Bayer AG, Novartis AG, Bristol-Myers Squibb, GSK, Pfizer Inc., Sarepta Therapeutics, Astellas Pharma Inc., and UniQure N.V. are actively pursuing product innovations and strategic partnerships. Among the leading players, Biogen stands out as a leader with its approved product Zolgensma for spinal muscular atrophy. Novartis is a significant competitor with its Zolgensma gene therapy for spinal muscular atrophy, the first approved treatment of its kind. In Q4 2024, the FDA approved PTC Therapeutics' Kebilidi, the first AAV gene therapy delivered directly into the brain. Do you think AAV gene therapy will eventually become the standard treatment for genetic disorders?

FAQs

What is the current market size of the AAV vector-based gene therapy market?
The market was valued at USD 5.718 billion in 2024 and is projected to reach USD 70.67 billion by 2035, exhibiting a CAGR of 25.68%.

Which segment dominates the AAV gene therapy market?
AAV9 holds the largest market share by vector serotype, while intravenous administration leads by route. Oncology represents the largest disease type segment.

Who are the key players in the AAV gene therapy market?
Key players include Spark Therapeutics, Bayer AG, Novartis AG, Bristol-Myers Squibb, GSK, Pfizer Inc., Sarepta Therapeutics, Astellas Pharma Inc., and UniQure N.V.

#AAVGeneTherapyMarket #GeneTherapy #GeneticDisorders #PrecisionMedicine #Biotechnology

Cerca
Categorie
Leggi tutto
Memes & Cultura da Comunidade
Multifunctional Composite Market Forecast & Growth Analysis
Acumen Research and Consulting (ARC) is a leading provider of The global market...
By Mugdha Bhide 2026-08-26 11:36:10 0 0
Lançamentos & Anúncios
A Competitive Landscape: Key Players and Strategies in the Nicorandil Preparations Market
The global Nicorandil preparations market is characterized by a competitive landscape where...
By Yogita Bankar 2026-09-15 07:23:36 0 0
Giochi
Hollow Knight's Steam Revival: Silksong's Halo Effect in 2025 and Beyond
When Hollow Knight: Silksong arrived in 2025, attention naturally shifted to Team Cherry's...
By Xtameem Xtameem 2026-11-08 05:26:06 0 0
Networking
Mechanical Electrical Plumbing Support System Market Growth Drivers Integrated MEP Support Solutions
As Per Market Research Future, the Mechanical Electrical Plumbing Support System Market Growth is...
By Mayuri Kathade 2026-01-20 10:01:35 0 0
Eventos & Convites
Telematics Market Expansion Accelerates Connected Mobility And Fleet Intelligence Worldwide
The Telematics Market is experiencing substantial growth as connected vehicle technologies...
By Akanksha Bhoite 2026-06-15 07:13:24 0 0